← Guardant Health overview
Guardant Health IncGH

Why is Guardant Health (GH) moving?

Q3 2026
▲3▼1

Guardant Health Q3 2026: Insurance Win, Strong Revenue, But Competition and Patent Costs Loom

  • UnitedHealth Coverage for Shield Test UnitedHealth became the first major insurer to cover Guardant's Shield colorectal cancer blood test, expanding access to over 100 million people. This should boost test volumes and revenue as more patients can afford the test.

    This is a major new commercial milestone that directly expands the addressable market for a key product.

  • Strong Q2 Revenue and Raised Guidance Q2 revenue rose 44% to $335 million, beating estimates, and full-year guidance was lifted to $1.34–1.36 billion. This shows accelerating growth and management confidence in the business.

    Financial results and guidance are core drivers of investor sentiment and stock price.

  • FDA and Europe Approve Guardant360 CDx for AstraZeneca Drug The FDA and Europe approved Guardant360 CDx for monitoring AstraZeneca's breast cancer drug, adding repeat-use revenue. This expands the test's clinical utility and creates a recurring revenue stream.

    Regulatory approvals open new markets and support long-term revenue growth.

  • Quest Launches Haystack MRD Nationwide and Patent Ruling Upheld Quest's Haystack MRD test launched nationwide, intensifying competition and potentially pressuring pricing and market share. A court also upheld a $245.2 million patent-infringement ruling plus a 6% royalty on certain sales through 2033, a real cash cost.

    These are significant headwinds that could limit growth and profitability, weighing on the stock.

September 2026
▲3▼1

Guardant's test approvals expand, but patent ruling adds a cost

  • FDA clears Guardant360 for breast cancer monitoring The FDA approved Guardant360 CDx as a companion test for AstraZeneca's new breast cancer drug Etcamah. This lets doctors use a simple blood draw every three months to catch treatment resistance early. It adds a new, repeat-use market for Guardant's flagship test, supporting revenue growth.

    This is a new regulatory approval that directly expands the market for Guardant's core product.

  • European approval extends the same breast cancer test Guardant360 CDx received CE-marking in Europe for the same Etcamah companion use. This opens the test to European patients and marks Guardant's 31st companion diagnostic approval. It broadens the addressable market beyond the U.S. and Japan, adding another long-term revenue stream.

    This is a new geographic expansion of the same test, increasing the potential patient pool.

  • Court orders $245 million patent payment A U.S. court upheld a jury verdict that Guardant infringed DNA sequencing patents, ordering $245.2 million in damages and royalties, plus a continuing 6% royalty on certain sales until 2033. Guardant plans to appeal. This is a real cash cost and a drag on future profits, though the appeal could reduce it.

    This is a new legal ruling with a concrete financial impact that weighs on earnings and sentiment.

  • Strong revenue growth beats peers Guardant reported quarterly revenue of $335 million, up 44.3% from a year earlier, beating analyst estimates by 6.4% — the biggest beat and fastest growth among testing and diagnostics peers. It also raised full-year guidance the most. This shows the business is scaling quickly and winning share.

    This is new financial data showing accelerating demand and execution, a core driver of the stock's value.

Latest
▲3▼1

Guardant's test approvals expand, but patent ruling adds a cost

  • FDA clears Guardant360 for breast cancer monitoring The FDA approved Guardant360 CDx as a companion test for AstraZeneca's new breast cancer drug Etcamah. This lets doctors use a simple blood draw every three months to catch treatment resistance early. It adds a new, repeat-use market for Guardant's flagship test, supporting revenue growth.

    This is a new regulatory approval that directly expands the market for Guardant's core product.

  • European approval extends the same breast cancer test Guardant360 CDx received CE-marking in Europe for the same Etcamah companion use. This opens the test to European patients and marks Guardant's 31st companion diagnostic approval. It broadens the addressable market beyond the U.S. and Japan, adding another long-term revenue stream.

    This is a new geographic expansion of the same test, increasing the potential patient pool.

  • Court orders $245 million patent payment A U.S. court upheld a jury verdict that Guardant infringed DNA sequencing patents, ordering $245.2 million in damages and royalties, plus a continuing 6% royalty on certain sales until 2033. Guardant plans to appeal. This is a real cash cost and a drag on future profits, though the appeal could reduce it.

    This is a new legal ruling with a concrete financial impact that weighs on earnings and sentiment.

  • Strong revenue growth beats peers Guardant reported quarterly revenue of $335 million, up 44.3% from a year earlier, beating analyst estimates by 6.4% — the biggest beat and fastest growth among testing and diagnostics peers. It also raised full-year guidance the most. This shows the business is scaling quickly and winning share.

    This is new financial data showing accelerating demand and execution, a core driver of the stock's value.

July 2026
▲2▼1

Guardant's Shield Wins Insurance Coverage and Sales Surge, Lifting Guidance

  • UnitedHealth covers Shield blood test UnitedHealth, America's largest commercial insurer, became the first big insurer to cover Guardant's Shield blood test for colorectal cancer screening. Over 100 million people can now get it. More covered patients means more test sales, pushing revenue and the stock up.

    This is a major new demand catalyst that directly expands the market for Guardant's key screening product.

  • Q2 revenue jumps 44%, guidance raised Guardant reported second-quarter revenue of $335 million, up 44% from a year ago, and raised its full-year 2026 revenue outlook to $1.34–$1.36 billion. Oncology test volume grew 63% and Shield screening revenue more than tripled. Strong growth signals the business is scaling, which supports a higher stock price.

    This is the latest hard financial evidence of accelerating demand and management confidence, a core driver of the stock.

  • Quest's Haystack MRD test goes nationwide Quest Diagnostics won New York approval for its Haystack MRD liquid biopsy test, clearing it for use in all 50 states. This puts a large, well-funded competitor directly into cancer monitoring, where Guardant also plays. More competition could pressure Guardant's pricing and market share, a real counterweight.

    It is a new competitive threat that could limit Guardant's growth in the cancer-monitoring market.

▲2▼1

Guardant's Shield Wins Insurance Coverage and Sales Surge, Lifting Guidance

  • UnitedHealth covers Shield blood test UnitedHealth, America's largest commercial insurer, became the first big insurer to cover Guardant's Shield blood test for colorectal cancer screening. Over 100 million people can now get it. More covered patients means more test sales, pushing revenue and the stock up.

    This is a major new demand catalyst that directly expands the market for Guardant's key screening product.

  • Q2 revenue jumps 44%, guidance raised Guardant reported second-quarter revenue of $335 million, up 44% from a year ago, and raised its full-year 2026 revenue outlook to $1.34–$1.36 billion. Oncology test volume grew 63% and Shield screening revenue more than tripled. Strong growth signals the business is scaling, which supports a higher stock price.

    This is the latest hard financial evidence of accelerating demand and management confidence, a core driver of the stock.

  • Quest's Haystack MRD test goes nationwide Quest Diagnostics won New York approval for its Haystack MRD liquid biopsy test, clearing it for use in all 50 states. This puts a large, well-funded competitor directly into cancer monitoring, where Guardant also plays. More competition could pressure Guardant's pricing and market share, a real counterweight.

    It is a new competitive threat that could limit Guardant's growth in the cancer-monitoring market.